183 related articles for article (PubMed ID: 19540126)
1. Computational selection of inhibitors of Abeta aggregation and neuronal toxicity.
Chen D; Martin ZS; Soto C; Schein CH
Bioorg Med Chem; 2009 Jul; 17(14):5189-97. PubMed ID: 19540126
[TBL] [Abstract][Full Text] [Related]
2. In-situ side-chain peptide cyclization as a breaker strategy against the amyloid aggregating peptide.
Ghosh N; Kundu LM
Bioorg Med Chem; 2021 Mar; 33():116017. PubMed ID: 33486160
[TBL] [Abstract][Full Text] [Related]
3. NABi, a novel β-sheet breaker, inhibits Aβ aggregation and neuronal toxicity: Therapeutic implications for Alzheimer's disease.
Jang JY; Rhim H; Kang S
Biochim Biophys Acta Gen Subj; 2018 Jan; 1862(1):71-80. PubMed ID: 29107146
[TBL] [Abstract][Full Text] [Related]
4. Mapping of possible binding sequences of two beta-sheet breaker peptides on beta amyloid peptide of Alzheimer's disease.
Hetényi C; Körtvélyesi T; Penke B
Bioorg Med Chem; 2002 May; 10(5):1587-93. PubMed ID: 11886820
[TBL] [Abstract][Full Text] [Related]
5. Retro-inversal of intracellular selected β-amyloid-interacting peptides: implications for a novel Alzheimer's disease treatment.
Acerra N; Kad NM; Griffith DA; Ott S; Crowther DC; Mason JM
Biochemistry; 2014 Apr; 53(13):2101-11. PubMed ID: 24601543
[TBL] [Abstract][Full Text] [Related]
6. How do membranes initiate Alzheimer's Disease? Formation of toxic amyloid fibrils by the amyloid β-protein on ganglioside clusters.
Matsuzaki K
Acc Chem Res; 2014 Aug; 47(8):2397-404. PubMed ID: 25029558
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of amyloid-β aggregation in Alzheimer's disease.
Wang Q; Yu X; Li L; Zheng J
Curr Pharm Des; 2014; 20(8):1223-43. PubMed ID: 23713775
[TBL] [Abstract][Full Text] [Related]
8. Disrupting beta-amyloid aggregation for Alzheimer disease treatment.
Estrada LD; Soto C
Curr Top Med Chem; 2007; 7(1):115-26. PubMed ID: 17266599
[TBL] [Abstract][Full Text] [Related]
9. β-sheet interfering molecules acting against β-amyloid aggregation and fibrillogenesis.
Francioso A; Punzi P; Boffi A; Lori C; Martire S; Giordano C; D'Erme M; Mosca L
Bioorg Med Chem; 2015 Apr; 23(8):1671-83. PubMed ID: 25769517
[TBL] [Abstract][Full Text] [Related]
10. Rationally Designed Peptides and Peptidomimetics as Inhibitors of Amyloid-β (Aβ) Aggregation: Potential Therapeutics of Alzheimer's Disease.
Goyal D; Shuaib S; Mann S; Goyal B
ACS Comb Sci; 2017 Feb; 19(2):55-80. PubMed ID: 28045249
[TBL] [Abstract][Full Text] [Related]
11. Amyloid-β Peptide Nitrotyrosination Stabilizes Oligomers and Enhances NMDAR-Mediated Toxicity.
Guivernau B; Bonet J; Valls-Comamala V; Bosch-Morató M; Godoy JA; Inestrosa NC; Perálvarez-Marín A; Fernández-Busquets X; Andreu D; Oliva B; Muñoz FJ
J Neurosci; 2016 Nov; 36(46):11693-11703. PubMed ID: 27852777
[TBL] [Abstract][Full Text] [Related]
12. Computational design and evaluation of β-sheet breaker peptides for destabilizing Alzheimer's amyloid-β
Shuaib S; Narang SS; Goyal D; Goyal B
J Cell Biochem; 2019 Oct; 120(10):17935-17950. PubMed ID: 31162715
[TBL] [Abstract][Full Text] [Related]
13. Molecular dynamics simulations of Aβ fibril interactions with β-sheet breaker peptides.
Bruce NJ; Chen D; Dastidar SG; Marks GE; Schein CH; Bryce RA
Peptides; 2010 Nov; 31(11):2100-8. PubMed ID: 20691234
[TBL] [Abstract][Full Text] [Related]
14. Identification of a Novel Multifunctional Ligand for Simultaneous Inhibition of Amyloid-Beta (Aβ
Asadbegi M; Shamloo A
ACS Chem Neurosci; 2019 Nov; 10(11):4619-4632. PubMed ID: 31566950
[TBL] [Abstract][Full Text] [Related]
15. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo.
Yang F; Lim GP; Begum AN; Ubeda OJ; Simmons MR; Ambegaokar SS; Chen PP; Kayed R; Glabe CG; Frautschy SA; Cole GM
J Biol Chem; 2005 Feb; 280(7):5892-901. PubMed ID: 15590663
[TBL] [Abstract][Full Text] [Related]
16. Breaker peptides against amyloid-β aggregation: a potential therapeutic strategy for Alzheimer's disease.
Ghosh N; Kundu LM
Future Med Chem; 2021 Oct; 13(20):1767-1794. PubMed ID: 34498978
[TBL] [Abstract][Full Text] [Related]
17. Modulating Aβ Fibrillogenesis with 'Trojan' peptides.
Pandey G; Morla S; Kumar S; Ramakrishnan V
Neuropeptides; 2020 Jun; 81():102030. PubMed ID: 32156470
[TBL] [Abstract][Full Text] [Related]
18. Design of peptide-based inhibitor agent against amyloid-β aggregation: Molecular docking, synthesis and in vitro evaluation.
Jokar S; Erfani M; Bavi O; Khazaei S; Sharifzadeh M; Hajiramezanali M; Beiki D; Shamloo A
Bioorg Chem; 2020 Sep; 102():104050. PubMed ID: 32663672
[TBL] [Abstract][Full Text] [Related]
19. Physicochemical characteristics of soluble oligomeric Abeta and their pathologic role in Alzheimer's disease.
Watson D; Castaño E; Kokjohn TA; Kuo YM; Lyubchenko Y; Pinsky D; Connolly ES; Esh C; Luehrs DC; Stine WB; Rowse LM; Emmerling MR; Roher AE
Neurol Res; 2005 Dec; 27(8):869-81. PubMed ID: 16354549
[TBL] [Abstract][Full Text] [Related]
20. α-Sheet secondary structure in amyloid β-peptide drives aggregation and toxicity in Alzheimer's disease.
Shea D; Hsu CC; Bi TM; Paranjapye N; Childers MC; Cochran J; Tomberlin CP; Wang L; Paris D; Zonderman J; Varani G; Link CD; Mullan M; Daggett V
Proc Natl Acad Sci U S A; 2019 Apr; 116(18):8895-8900. PubMed ID: 31004062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
